Alemtuzumab C₆₄₆₈H₁₀₀₆₆N₁₇₃₂O₂₀₀₅S₄₀

Therapeutic indications

Alemtuzumab is indicated for:

Relapsing remitting multiple sclerosis (RRMS)

Population group: both men and women, only adults (18 years old or older)

Alemtuzumab is indicated as a single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (RRMS) for the following patient groups:

  • Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) or
  • Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Alemtuzumab is contraindicated in the following cases:

Human Immunodeficiency Virus (HIV) infection

Human immunodeficiency virus infection (disorder)

Pregnancy

Pregnancy

Severe active infection

Infectious disease (disorder)

Lactation

Lactation

Hypertension

Hypertensive disorder, systemic arterial (disorder)

Arterial dissection of the cervicocephalic arteries

Dissection of cervicocerebral artery (disorder)

Stroke

at least one of
Cerebrovascular accident (disorder)
History of cerebrovascular accident (situation)

Angina pectoris, myocardial infarction

at least one of
History of angina pectoris (situation)
Angina (disorder)
Myocardial infarction (disorder)
History of myocardial infarction (situation)

Coagulopathy, anti-platelets, anti-coagulants

at least one of
Blood coagulation disorder (disorder)
Antithrombotic agents

Concomitant autoimmune diseases

Autoimmune disease (disorder) and additionally not
Relapsing remitting multiple sclerosis (disorder)

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: LEMTRADA Concentrate for solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈